Compare AstraZeneca plc (AZN) vs Monolithic Power Systems Inc (MPWR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Monolithic Power Systems Inc — how do they compare? AstraZeneca plc trades at $166.87 (market cap $253.13B), while Monolithic Power Systems Inc trades at $1,394 (market cap $67.62B). The key difference: AstraZeneca plc is far larger — about 3.7× Monolithic Power Systems Inc's market cap, and AstraZeneca plc pays the higher dividend (1.92%). Which is the better fit depends on your goals.
| AZN | MPWR | |
|---|---|---|
Market Cap | $253.13B | $67.62B |
Sector | Health | Utilities |
52-Week High | $209.48 | $1.69K |
52-Week Low | $137.44 | $711.24 |
Enterprise Value | $279.37B | $66.28B |
Dividend Yield | 1.92% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
Monolithic Power Systems (MPWR) trades at $1,291.38, down 4.54% on the day, amid a bearish technical signal despite strong fundamentals. The stock shows robust profitability with 22.98% net income margin and has beaten earnings estimates for three consecutive quarters. Analyst consensus remains strongly bullish with 88% buy ratings and a $1,760 price target, representing significant upside potential from current levels.
The stock presents a compelling growth opportunity driven by AI infrastructure demand and power semiconductor trends, though elevated valuation multiples and ongoing legal investigations pose risks. Technical indicators suggest near-term weakness, but strong institutional support and consistent earnings performance support the long-term bullish case for investors seeking exposure to semiconductor growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Monolithic Power Systems Inc
Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.
Read more on MPWR →
